Now Playing
|Videos|January 24, 2023
Prevalence of Hypothyroidism in a Commercially Insured US Population: Overview and Trial Design
Alex Tessnow M.D. provides a brief overview of the study rationale and design of the recently presented poster highlighting the prevalence of hypothyroidism in a commercially insured US population.
Advertisement
Episodes in this series
Advertisement
Related to this article
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
New Study Shows Menopause Undercoded in Primary Care, With Gaps by Race and Insurance
3
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
4
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
5